Tianle Zhang

Title: Innovations of Tianle Zhang in Antitumor Drug Delivery Systems

Introduction

Tianle Zhang is an accomplished inventor based in Tianjin, China. He has made significant contributions to the field of antitumor drug delivery systems. His innovative work focuses on enhancing the efficacy and targeting of antitumor drugs, which is crucial in cancer treatment.

Latest Patents

Tianle Zhang holds a patent for a "Ternary conjugate of antitumor drug, and synthesis and application." This patent discloses a targeted delivery system for a hydrophobic antitumor drug. The system involves conjugates of E-selectin polypeptide ligand, polyethylene glycol, and the antitumor drug, connected by different link bridges containing disulfide bonds. The patent details the synthesis of these conjugates, evaluation of their antitumor activity, and the characteristics of nanoparticles self-assembled from the conjugates in an aqueous solution. The conjugates are designed to actively target tumor sites through the E-selectin peptide ligand and can self-assemble into nanoparticles, allowing for passive targeting via the enhanced permeability and retention (EPR) effect. The results indicate that these conjugates exhibit significant antitumor activity while being less toxic to normal cells. They also have the potential to inhibit the adhesion between tumor cells and vascular endothelial cells, showcasing promise in the development and application of antitumor drugs.

Career Highlights

Tianle Zhang is affiliated with Tianjin University of Science and Technology, where he conducts his research and development work. His innovative approach to drug delivery systems has positioned him as a notable figure in the field of cancer research.

Collaborations

Tianle Zhang collaborates with esteemed colleagues, including Peng Yu and Na Guo, who contribute to his research endeavors. Their combined expertise enhances the potential impact of their work in the field of antitumor drug development.

Conclusion

Tianle Zhang's contributions to antitumor drug delivery systems represent a significant advancement in cancer treatment. His innovative patent highlights the potential for targeted therapies that can improve patient outcomes while minimizing side effects.